 |
pembrolizumab |
|---|---|
| Trade Name | Keytruda |
| Orphan Indication | Hodgkin’s disease |
| USA Market Approval | USA |
| USA Designation Date | 2015-12-30 00:00:00 |
| Sponsor | Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc;126 E. Lincoln Avenue, P. O. Box 2000;Rathway, Pennsylvania, 07065 |
